Citations

Mayo Clinic

Showing 10 of 108572 citations.

Functional Return‐to‐Sport Testing Demonstrates Inconsistency in Predicting Short‐Term Outcomes Following Anterior Cruciate Ligament Reconstruction: A Systematic Review
Gill, Vikram S. , Tummala, Sailesh V. , Sullivan, Georgia , Han, Will, Haglin, Jack M. , Marks, Lisa , Tokish, John M. , Marks, Lisa A , Tummala, Sailesh V

Arthroscopy | January 11, 2024 | Volume: 40 | Issue: 7 | Pages: 2135

10.1016/j.arthro.2023.12.032 | PMID 38216071 Get It

Purpose To systematically review the relationship between functional testing at the time of return to sport (RTS) and short‐term outcomes, such as second anterior cruciate ligament (ACL) tear and return to a preinjury level of sport, among athletes who underwent anterior cruciate ligament reconstruction (ACLR). Methods A systematic literature search was performed in MEDLINE, EMBASE, Scopus, and Web of Science to identify studies examining athletes who underwent functional RTS testing and were followed for at least 12 months following ACLR. Studies were screened by 2 reviewers. A standardized template was used to extract information regarding study characteristics, ACLR information, functional test results, and risk factors associated with retear or reduced RTS. Results Of the 937 studies identified, 22 met the inclusion criteria. The average time between ACLR and RTS testing was 8.5 months. Single leg hop for distance performance had no association with retear risk in any study and no association with RTS rates in most studies. Quadriceps strength had conflicting results in relation to retear risk, whereas it had no relationship with RTS rates. Rates of reinjury and RTS were similar between patients who passed and did not pass combined hop and strength batteries. Asymmetric knee extension and hip moments, along with increased knee valgus and knee flexion angles, demonstrated increased risk of retear. Conclusions Individual hop and strength tests that are often used in RTS protocols following ACLR may have limited and inconsistent value in predicting ACL reinjury and reduced RTS when used in isolation. Combined hop and strength test batteries also demonstrate low sensitivity and negative predictive value, highlighting conflicting evidence to suggest RTS testing algorithm superiority. Level of Evidence Level IV, systematic review of Level I‐IV studies.
Novel Neuroimaging Pattern in POLR3A -Related Disorder on 7T MRI
Dulski, Jarosław , Middlebrooks, Erik H. , Wszołek, Zbigniew K. , Wszolek, Z.K. , Middlebrooks, Erik H , Dulski, Jaroslaw

Neurology Genetics | January 10, 2024 | Volume: 10 | Issue: 1 | Pages: No page available

10.1212/nxg.0000000000200125 | PMID 38213753 Get It

Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies
Figueroa‐Parra, Gabriel , Putman, Michael , Crowson, Cynthia S. , Duarte‐García, Alí , Duarte-García, Alí , Figueroa-Parra, Gabriel

Lupus Science & Medicine | January 10, 2024 | Volume: 11 | Issue: 1 | Pages: e001068

10.1136/lupus-2023-001068 | PMID 38199863 Get It

Objective We aimed to evaluate the robustness of phase III randomised controlled trials (RCTs) for SLE and lupus nephritis (LN) using the fragility index (FI), the reverse FI (RFI) and the fragility quotient (FQ). Methods We searched for phase III RCTs that included patients with active SLE or LN. Data on primary endpoints, total participants and the number of events for each arm were obtained. We calculated the FI score for RCTs with statistically significant results (number of patients required to change from event to non-event to make the study lose statistical significance), the RFI for RCTs without statistically significant results (number of patients required to change from non-event to event to make study gain statistical significance) and the FQ score for both (FI or RFI score divided by the sample size). Results We evaluated 20 RCTs (16 SLE, four LN). The mean FI/RFI score was 13.6 (SD 6.6). There were nine RCTs with statistically significant results (seven SLE, two LN), and the mean FI score was 10.2 (SD 6.2). The lowest FI was for the ILLUMINATE-2 trial (FI=2), and the highest FI was for the BLISS-52 trial (FI=17). Twelve studies had non-statistically significant results (10 SLE, two LN) with a mean RFI score of 15.6 (SD 6.1). The lowest RFI was for the ILLUMINATE-1 trial (RFI=4), and the highest RFI was for the TULIP-1 trial (RFI=27). The lowest FQ scores were found in the ILLUMINATE trials and the highest in the Rituximab trials (EXPLORER and LUNAR), meaning that the last ones were the most robust results after accounting for sample size. Conclusions The evidence of therapies for patients with SLE and LN is derived mostly from fragile RCTs. Clinicians and trialists must be aware of the fragility of these RCTs for clinical decision-making and designing trials for novel therapeutics.
Ultrasound Shear Elastography With Expanded Bandwidth (USEWEB): A Novel Method for 2D Shear Phase Velocity Imaging of Soft Tissues
Kijanka, Piotr , Urban, Matthew W. , Urban, Matthew W

IEEE Transactions on Medical Imaging | January 10, 2024 | Volume: 43 | Issue: 5 | Pages: 1910-1922

10.1109/tmi.2024.3352097 | PMID 38198276 Get It

Development of a flipped learning course to deliver and scale molecular variant evaluation education: A quality improvement initiative
Balcom, Jessica R. , Ellingson, Marissa S. , Bowler, Carrie , Richardson, Darcy M., Kruisselbrink, Teresa , Thomas, Brittany C. , Bowler, Carrie A

Journal of Genetic Counseling | January 10, 2024 | Volume: 33 | Issue: 1 | Pages: 168-178

10.1002/jgc4.1855 | PMID 38197720 Get It

AbstractOver the past several decades, molecular genetic testing volumes have grown and testing has expanded from single‐gene assays to multigene panels, exome sequencing, and genome sequencing. The number of molecular genetic variants that require manual interpretation has grown simultaneously, resulting in an increased demand for education on molecular variant evaluation (MVE). To meet this growing need, a team of genetic counselors and educational experts undertook a quality improvement (QI) initiative with the objectives of assessing, standardizing, and scaling access to MVE education, without increasing instructor time to deliver the education. Using the Six Sigma define–measure–analyze–improve–control (DMAIC) framework, a flipped learning course with a series of standardized online modules was developed to deliver MVE education in an enduring and accessible format for a diverse group of learners. Outcome measures included the number of online modules developed, the number of individual learners and unique learner groups accessing MVE education, and direct instruction time required to deliver MVE education. Countermeasures to ensure maintenance of educational quality included post‐course learner satisfaction scores and performance on competency assessments. Both the total number of learners and the number of unique learner groups accessing MVE education increased, while instructor time required to deliver content per learner decreased. Learner satisfaction scores remained constant and performance on competency assessments improved. The QI initiative successfully scaled MVE education to a diverse group of learners without decreasing learner outcomes or satisfaction. The flipped learning format provides a scalable and flexible educational model for instructors and learners in a rapidly changing environment that often includes remote work and education.
A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow‐up
Anderson, Larry D. , Bladé, Joan , Kyle, Robert A. , Anderson, Larry D

eJHaem | January 10, 2024 | Volume: 5 | Issue: 1 | Pages: 235-237

10.1002/jha2.846 | PMID 38406530 Get It

AbstractThe presence of a serum immunoglobulin D (IgD) monoclonal protein (M‐protein) is seen in < 1% of patients with monoclonal gammopathies and is usually indicative of a malignant plasma cell disorder. Only a few cases of well‐documented benign monoclonal gammopathy of undetermined significance (MGUS) of IgD subtype have been reported, and only 2 of those had over 5 years of follow‐up at the time they were reported. Herein we describe longer‐term follow‐up of one of those 2 patients who has subsequently passed away from unrelated causes but never developed multiple myeloma or amyloidosis after 26 years of follow‐up. Although IgD MGUS is extremely rare, this case confirms that presence of an IgD M‐Protein is not always synonymous with a malignant plasma cell process.
Superior Ethmoidal Approach to an Olfactory Groove Meningioma: Maximizing Preservation of Nasal Anatomy: 2-Dimensional Operative Video
Alexander, A. Yohan , Agosti, Edoardo, Peris‐Celda, Maria , Alexander, A Yohan , Agosti, Edoardo , Pinheiro‐Neto, Carlos

Operative Neurosurgery | January 10, 2024 | Volume: 26 | Issue: 6 | Pages: 763-764

10.1227/ons.0000000000001059 | PMID 38198187 Get It

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Zhang, Ting , Bouchonville, Kelly J. , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

No container title available | January 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.1 Get It

Abstract Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.